The co-antibody therapy JNJ-4804 -- a fixed-dose combination of guselkumab (Tremfya) and golimumab (Simponi) -- showed clinically meaningful efficacy exceeding that of either drug alone in patients ...

For too long you have suffered from inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). Crohn’s disease.

Arthritis is the most common nonintestinal complication for people with ulcerative colitis (UC). These tips can help stave it ...

IBD is an immune condition. Instead of peacefully coexisting with gut microbes, the immune system becomes overly reactive, ...

Inflammatory bowel disease (IBD), affecting an estimated 6–8 million people worldwide, may soon be monitored with a simple ...

Black, Hispanic and female patients with ulcerative colitis were significantly less likely to undergo colectomy compared with ...

Chronic immune diseases are shaped by multiple inflammatory processes happening at the same time, each in different parts of ...

For patients with Crohn disease and ulcerative colitis (UC), a fixed-dose co-antibody therapy JNJ-4804 is efficacious.

Net loss attributable to Xencor for the first quarter ended March 31, 2026 was $128.9 million, or $ (1.71) on a fully diluted per share basis, compared to net loss of $48.4 million, or $ (0.66) on a ...

A new fixed-dose co-antibody therapy appears to be effective for managing ulcerative colitis and Crohn disease.

On April 16, 2026, the U.S. Food & Drug Administration (FDA) announced it will convene the Pharmacy Compounding Advisory Committee (PCAC) on July ...

Scientists have uncovered an unexpected mechanism by which the gut’s immune system maintains balance, challenging ...